Patisiran
ALN-TTRSC02-002
Phase 3 small_molecule completed
Quick answer
Patisiran for Amyloidosis, Hereditary is a Phase 3 program (small_molecule) at Alnylam Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Alnylam Netherlands B.V.
- Indication
- Amyloidosis, Hereditary
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed